Inhibitors of Sa-Reductase
Abstract
The enzyme steroid Sa-reductase (SAR) catalyzes the c nversion of Ll4 steroids to the corresponding saturated steroids and plays a significant role in developmental biology. Dihydrotestosterone, a product of Sa-reduction of testosterone, has been implicated in the pathology of benign prostatic hyperplasia, acne and male pattern baldness. Two isozymes of SAR are now known and the relative roles of these enzymes in developmental physiology and in the pathophysiology of androgen related disorders is the subject of much current research. Progress in the development of potent isozyme selective and dual inhibitors of SAR is reviewed with an emphasis on structure activity relationships as well as efficacy in animal models of benign prostatic hyperplasia and human clinical studies.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.